摘要
目的探讨凝血指标及部分肿瘤标志物与不同分期恶性肿瘤合并静脉血栓栓塞症(VTE)之间的关系。方法选取2013年5月~2017年1月新疆医科大学第三临床医学院收治的恶性肿瘤合并VTE患者233例作为研究对象。依据恶性肿瘤TNM分期标准,将其分为Ⅰ组(17例)、Ⅱ组(17例)、Ⅲ组(54例)、Ⅳ组(145例)。比较四组D-二聚体(D-D)、凝血酶原时间(PT)、活化部分凝血酶原时间(APTT)、纤维蛋白原(Fbg)、国际标准化比值(INR)及糖类抗原19-9(CA19-9)、CA125、癌胚抗原(CEA)水平。结果Ⅲ组D-D值高于Ⅰ~Ⅱ组(P <0.05);Ⅳ组D-D值高于Ⅰ~Ⅲ组(P <0.05);四组PT、APTT、Fbg、INR水平比较,差异无统计学意义(P> 0.05)。Ⅲ组CA19-9水平高于Ⅱ组(P <0.05);Ⅳ组CA19-9、CA125水平高于Ⅰ~Ⅲ组(P <0.05);Ⅲ~Ⅳ组CEA水平高于Ⅰ~Ⅱ组(P <0.05)。结论分期较晚的患者更应密切关注D-D及CA19-9、CA125、CEA水平,也可适当提高检测频率,以监测其血栓状态。
Objective To explore the relationship between coagulation parameters and tumor markers and venous thromboembolism(VTE)in different stages of malignant tumors.Methods A total of 233 patients with malignant tumors complicated with VTE who admitted to the Third Clinical Medical College of Xinjiang Medical University from May2013 to January 2017 were selected as research objects.According to the malignant tumor TNM staging criteria,they were divided into groupⅠ(17 cases),groupⅡ(17 cases),groupⅢ(54 cases),groupⅣ(145 cases).D-dimer(D-D),prothrombin time(PT),activated partial prothrombin time(APTT),fibrinogen(Fbg),international normalized ration(INR)and Glycan 19-9(CA19-9),CA125,Carcinoembryonic Antigen(CEA)were compared between four groups.Results DD value in groupⅢwas higher than that in groupⅠ-Ⅱ(P<0.05);D-D value in groupⅣwas higher than that in groupⅠ-Ⅲ(P<0.05);and there were no significant differences in PT,APTT,Fbg,INR levels between four groups(P>0.05).CA19-9 levels in groupⅢwere higher than those in groupⅡ(P<0.05);CA19-9,CA125 levels in groupⅣwere higher than those in groupⅠ-Ⅲ(P<0.05);CEA levels in groupⅢ-Ⅳwere higher than those in groupⅠ-Ⅱ(P<0.05).Conclusion Patients with late stage should pay more attention to D-D and CA19-9,CA125 and CEA levels,and the detection frequency can be appropriately increased to monitor their thrombus status.
作者
何丽丽
曹国磊
罗琴
HE Lili;CAO Guolei;LUO Qin(Department of Integrated Internal Medicine,the Third Clinical Medical College,Xinjiang Medical University,Xinjiang Uygur Autonomous Region,Urumqi 830011,China)
出处
《中国医药导报》
CAS
2020年第17期117-120,共4页
China Medical Herald
基金
国家自然科学基金资助项目(81760014)。
